Mosunetuzumab: A Comprehensive Clinical and Scientific Review of a First-in-Class Bispecific T-Cell Engager for Relapsed/Refractory Follicular Lymphoma

Introduction to Mosunetuzumab: A Novel Bispecific T-Cell Engager in Follicular Lymphoma

The Unmet Need in Relapsed/Refractory Follicular Lymphoma (R/R FL)

Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma (NHL) and is generally characterized by an indolent, or slow-growing, clinical course.[1] While it is considered a treatable disease, it is typically incurable with standard therapeutic approaches. The natural history of FL involves a pattern of remission and relapse, where patients often respond well to initial treatments but subsequently experience disease recurrence.[3] With each successive line of therapy, the duration of response and progression-free survival tends to shorten, and the disease may become increasingly refractory to treatment.[3]

A significant unmet clinical need exists for patients with relapsed or refractory (R/R) FL who have progressed after two or more prior lines of systemic therapy. This patient population has often been exposed to, and may be refractory to, standard-of-care agents, including an anti-CD20 monoclonal antibody such as rituximab and an alkylating agent.[5] For these heavily pretreated individuals, therapeutic options are limited, and prognoses are often poor, underscoring the urgent need for novel agents with distinct mechanisms of action and durable efficacy.

Introducing Mosunetuzumab (Lunsumio): A First-in-Class Therapeutic